Drug Profile
Fispemifene - Forendo Pharma
Alternative Names: HM-101Latest Information Update: 20 Dec 2021
Price :
$50
*
At a glance
- Originator Hormos Medical
- Developer Apricus Biosciences; Forendo Pharma
- Class Alcohols; Osteoporosis therapies; Small molecules; Stilbenes
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hypogonadism
Most Recent Events
- 13 Dec 2021 Forendo Pharma has been acquired by Organon
- 25 Jan 2019 Seelos Therapeutics merged with Apricus Biosciences to form Seelos Therapeutics
- 13 Mar 2018 Phase II development in Hypogonadism is ongoing Finland